A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Clinical trial NCT06692738 · RECRUITING
Trial details
- NCT number
- NCT06692738
- Sponsor
- AstraZeneca
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2024-11-18
- Primary completion
- 2030-07-01
- Enrollment
- 1160
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.